Section 1 Prophylactic Cranial Irradiation for Extensive-Stage SCLC
	Click here to download entire section
Track 1	Critical evaluation of the EORTC trial of prophylactic cranial irradiation (PCI) for extensive-stage SCLC
Track 2	Clinical implications of the EORTC PCI trial
Track 3	Cognitive dysfunction in patients receiving PCI

Section 2 Bevacizumab in Advanced NSCLC
	Click here to download entire section
Track 1	AVAiL: Cisplatin/gemcitabine with or without bevacizumab for chemotherapy-naïve patients with advanced or recurrent nonsquamous NSCLC
Track 2	Methodologic issues in the AVAiL study
Track 3	Clinical implications of the AVAiL study
Track 4	Dose of bevacizumab and chemotherapy doublet off protocol
Track 5	Interval between induction chemotherapy/bevacizumab and surgery
Track 6	Activity of single-agent bevacizumab in NSCLC
Track 7	Combining bevacizumab with established chemotherapy regimens for advanced NSCLC
Track 8	Management of a bevacizumab-associated antitumor cavitary response
Track 9	Central tumor location and risk of fatal hemoptysis with bevacizumab
Track 10	Contraindications to bevacizumab in NSCLC
Track 11	Cisplatin versus carboplatin for advanced disease
Track 12	Factors to consider when selecting an adjuvant chemotherapy regimen

Section 3 Surgery for NSCLC
	Click here to download entire section
Track 1	Adequacy of lymph node dissection
Track 2	Restaging an inadequately sampled mediastinum
Track 3	Dissection of mediastinal nodes in community practice
Track 4	Performance of lung cancer surgery by general versus thoracic surgeons

Section 4 Adjuvant Clinical Trials in NSCLC
	Click here to download entire section
Track 1	Feasibility of completing a clinical trial of adjuvant therapy for patients with Stage IA or IB NSCLC
Track 2	Feasibility of completing accrual to ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab for Stage IB (greater than or equal to 4 cm) to IIIA NSCLC
Track 3	Anticipated patient acceptance of one year of adjuvant bevacizumab in E1505
Track 4	Barriers to enrollment on adjuvant clinical trials in lung cancer
Track 5	Role of surgeons in facilitating accrual to adjuvant clinical trials in lung cancer
Track 6	Early closure of the CALGB-9633 adjuvant trial in Stage IB NSCLC
Track 7	Benefit of adjuvant chemotherapy for patients with Stage IB NSCLC

Section 5 EGFR Tyrosine Kinase Inhibitors
	Click here to download entire section
Track 1	Predictors of response to the EGFR tyrosine kinase inhibitors (TKIs)
Track 2	Offering erlotinib as first-line therapy for metastatic NSCLC in patients with positive predictors of response
Track 3	Activity of erlotinib in nonenriched patient populations
Track 4	Assessment of EGFR mutation status in community practice
Track 5	Smoking history as a predictor of response to erlotinib
Track 6	Proportion of patients with newly diagnosed NSCLC who are oligosmokers or never smokers
Track 7	Management of EGFR TKI-associated rash

Section 6 Stage III NSCLC
	Click here to download entire section
Track 1	Identifying appropriate patients with Stage III NSCLC for treatment with neoadjuvant chemotherapy with or without radiation therapy
Track 2	Surgical mortality associated with preoperative chemotherapy with and without radiation therapy
Track 3	Value of surgery after neoadjuvant chemotherapy or chemoradiation therapy for patients with Stage III disease
Track 4	Clinical trial strategies incorporating biologics with chemoradiation therapy for Stage III NSCLC
Track 5	Factors contributing to pneumonitis with the SWOG-S9504 treatment approach to Stage III NSCLC
Track 6	Clinical implications of the negative results from the randomized HOG LUN 01-24 trial
Track 7	Balancing local versus systemic control of Stage III NSCLC
Track 8	Selecting a chemotherapy regimen to combine with radiation therapy for Stage III NSCLC
Track 9	Incorporation of biologics with chemoradiation therapy in Stage III NSCLC
Track 10	Potential for reduced long-term neurotoxicity with nab paclitaxel in lung cancer
Track 11	Efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib versus chemotherapy alone for recurrent or refractory NSCLC

Section 7 Novel Molecularly Targeted Agents in Lung Cancer
	Click here to download entire section
Track 1	Clinical strategies to evaluate the molecularly targeted agent vandetanib in lung cancer
Track 2	Vandetanib-associated side effects

Section 8 Treatment of the Elderly
	Click here to download entire section
Track 1	Phase III randomized trial of weekly docetaxel versus docetaxel/gemcitabine for Stage IIIB/IV NSCLC in elderly patients or those with poor performance status
Track 2	Age and benefit and toxicity from lung cancer treatment
Track 3	Pitfalls and limitations of clinical decision-making based on subset analyses
Track 4	Treatment-related deaths among the elderly in ECOG-E4599
Track 5	Adjuvant therapy for the elderly patient with lung cancer
Track 6	Treatment of elderly patients with symptom-related PS2, advanced NSCLC